Epigenomics AG
EPGNF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | 98.18% | 72.26% | -564.41% | -589.75% |
| EV / EBITDA | 53.51 | 4.02 | 1.30 | 1.36 |
| Quality | ||||
| ROIC | 15.62% | 17.22% | -114.62% | -112.46% |
| Gross Margin | 89.64% | 89.79% | 92.86% | 71.64% |
| Cash Conversion Ratio | 0.20 | 0.20 | 1.21 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -62.04% | -61.14% | -15.52% | -10.75% |
| Free Cash Flow Growth | 0.00% | 111.93% | 3.52% | 25.79% |
| Safety | ||||
| Net Debt / EBITDA | 51.48 | 3.82 | 1.58 | 1.49 |
| Interest Coverage | 0.00 | 0.00 | -376.29 | -809.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,303.11 | 395.46 | -9,123.43 | -6,943.61 |